Acquisition Synergy PSG was acquired by Fujirebio Holdings, Inc, expanding its role as a supplier of high quality biological raw materials to the IVD and life sciences sectors. This creates cross sell and channel expansion opportunities with Fujirebio's customer base, enabling sales teams to position PSG's donor recruitment network and disease state sourcing as a value add for diagnostics developers and contract manufacturers.

Donor Network Asset PSG's national donor recruitment program and capability to source materials tied to specific disease states is a unique asset for R&D and manufacturing teams in the IVD space. Use this to offer access to diverse biological materials for assay development, validation, and reference materials.

Quality and Experience With over three decades in the medical device field and a formal quality policy, PSG demonstrates reliability and strong supplier relationships. This can be positioned to customers seeking compliant sourcing and turnkey production and engineering services for early stage to scale up manufacturing.

Global Market Position Despite a lean team, PSG positions itself as an industry leader with global reach in supplying biological materials and antibody collection services for worldwide medical device markets. This presents opportunities to engage larger customers or partners seeking scalable, quality materials with engineering support.

IVD Materials Demand There is sustained demand for high quality biological materials and antibody based solutions in the IVD and life sciences markets. PSG offers end to end capabilities from sourcing to manufacturing and engineering, presenting a compelling value proposition for diagnostics developers and CROs seeking reliable supply partners.